- Biomarker Services
- Companion Diagnostic Development
- Biomarker Clinical Trial Management
- Internal Biomarker Discovery
- Proprietary Discovery Arrays
- Genomic Services
- Bioinformatics Consultancy
- FFPE Solutions
Predictive and Prognostic Tests
At Almac we are developing both predictive and prognostic tests to answer specific clinical questions.
Our approach to generating predictive tests is to identify molecular subtypes within large clinical datasets that are defined by specific biological processes. We focus on biological processes that facilitate the mechanism of action of targeted therapeutics.
We then develop a molecular signature or classifier that can identify patients that have aberrant signalling in this process.
This signature can then be used for patient stratification in clinical trials where drugs that target this biological process are being tested.
In addition the signature can be further developed as a companion diagnostic from specific drugs that target this biological process.
In many diseases such as colon and lung cancer, there is currently no way of identifying those who are at high risk of disease recurrence after surgery and who may benefit from adjuvant chemotherapy.
In the case of colon cancer, we have generated a prognostic signature which can correctly identify high risk individuals and are currently developing this into a diagnostic test.
We are in the process of developing a similar signature for early stage lung cancer and metastatic prostate cancer.